US FDA, United States
Disclosure information not submitted.
Assessment of Potential Adverse Events Following the 2022–2023 Seasonal Influenza Vaccines Among U.S. Adults Aged 65 Years and Older
Monday, August 26, 20242:30 PM – 2:45 PM CEST
Effectiveness Over Time of a Complete Primary Series of the Original, Monovalent COVID-19 Vaccines Among Adults Aged 18-64 Years in the United States
Tuesday, August 27, 20249:15 AM – 9:30 AM CEST
